Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2015-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ymgme.2015.05.005PMID 25982063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods.

  2015cited by this paper
• Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)

  2014cited by this paper
• Classification and Natural History of the Neuronal Ceroid Lipofuscinoses

  2013cited by this paper
• Neuroprotection and lifespan extension in Ppt1−/− mice by NtBuHA: therapeutic implications for INCL

  2013cited by this paper
• Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).

  2013cited by this paper
• Synergistic effects of central nervous system‐directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis

  2012cited by this paper
• Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses

  2012cited by this paper
• CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder

  2012cited by this paper
• Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis

  2012cited by this paper
• Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.

  2012cited by this paper
• Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.

  2011cited by this paper
• Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol.

  2011cited by this paper
• The Role of Attenuated Astrocyte Activation in Infantile Neuronal Ceroid Lipofuscinosis

  2011cited by this paper
• Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.

  2011cited by this paper
• Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis.

  2010cited by this paper
• A Murine Model of Infantile Neuronal Ceroid Lipofuscinosis—Ultrastructural Evaluation of Storage in the Central Nervous System and Viscera

  2008cited by this paper
• Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1

  2007cited by this paper
• Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis.

  2007cited by this paper
• CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis.

  2006cited by this paper
• Thematic review series: Lipid Posttranslational Modifications. Lysosomal metabolism of lipid-modified proteins Published, JLR Papers in Press, April 20, 2006.

  2006cited by this paper
• Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier.

  2004cited by this paper
• Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis.

  2004cited by this paper
• Disruption of PPT2 in mice causes an unusual lysosomal storage disorder with neurovisceral features

  2003cited by this paper
• Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice

  2001cited by this paper
• Adult neuronal ceroid lipofuscinosis with palmitoyl‐protein thioesterase deficiency: First adult‐onset patients of a childhood disease

  2001cited by this paper
• Hematopoietic stem cell transplantation in infantile neuronal ceroid lipofuscinosis

  2001cited by this paper
• A rapid fluorogenic palmitoyl-protein thioesterase assay: pre- and postnatal diagnosis of INCL.

  1999cited by this paper
• Molecular genetics of palmitoyl-protein thioesterase deficiency in the U.S.

  1998cited by this paper
• Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis

  1995cited by this paper

• Enzyme replacement therapy for CLN1 batten disease that crosses the blood-brain-barrier.

  2026cites this paper
• Molecular elucidation of brain lipofuscin in aging and Neuronal Ceroid Lipofuscinosis

  2025cites this paper
• Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets

  2025cites this paper
• Developing Treatments for Rare Diseases on a Shoestring

  2023cites this paper
• Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme

  2022influential citation
• Targeting the Central Nervous System in Lysosomal Storage Diseases: Strategies to Deliver Therapeutics Across the Blood-Brain Barrier.

  2022cites this paper
• Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep

  2022cites this paper
• Transduction characteristics of alternative adeno-associated virus serotypes in the cat brain by intracisternal delivery

  2022cites this paper
• Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.

  2022cites this paper
• Lysosomal Storage Disorders

  2021cites this paper
• Ocular Manifestations of Neuronal Ceroid Lipofuscinoses

  2021cites this paper
• Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy

  2020cites this paper
• Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities

  2020cites this paper
• Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease

  2020cites this paper
• Urine proteomics analysis of patients with neuronal ceroid lipofuscinoses

  2020cites this paper
• Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.

  2020cites this paper
• Batten disease: an expert update on agents in preclinical and clinical trials

  2020cites this paper
• Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery

  2019cites this paper
• Therapeutic landscape for Batten disease: current treatments and future prospects

  2019cites this paper
• Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses

  2019cites this paper
• Next-Generation Sequencing Analysis Reveals Novel Pathogenic Variants in Four Chinese Siblings With Late-Infantile Neuronal Ceroid Lipofuscinosis

  2019cites this paper
• Analysis of Brain and Cerebrospinal Fluid from Mouse Models of the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Changes in the Lysosomal Proteome*

  2019cites this paper
• The contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research.

  2019cites this paper
• Investigating the effects of repeat ketamine exposure : linking brain structural imaging changes to cellular alterations

  2019cites this paper
• An update on the progress of preclinical models for guiding therapeutic management of neuronal ceroid lipofuscinosis

  2019cites this paper
• Characteristics of PPT1 and TPP1 enzymes in neuronal ceroid lipofuscinosis (NCL) 1 and 2 by dried blood spots (DBS) and leukocytes and their application to newborn screening.

  2018cites this paper
• Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders.

  2017cites this paper
• Drug and Gene Delivery to the Central Nervous System for Neuroprotection

  2017cites this paper
• Translating preclinical models of neuronal ceroid lipofuscinosis: progress and prospects

  2017influential citation
• Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease

  2017cites this paper
• Discovering disease causing variants in dogs through whole genome sequencing

  2017cites this paper
• Synergistic effects of treating the spinal cord and brain in CLN1 disease

  2017cites this paper
• Viral Vector Gene Delivery to the Brain for Treating Neurogenetic Diseases

  2017cites this paper
• Juvenile NCL (CLN3 Disease): Emerging Disease-Modifying Therapeutic Strategies.

  2016cites this paper
• The Neuronal Ceroid Lipofuscinoses: A Case-Based Overview

  2016cites this paper
• Infantile Batten Disease: Effective Therapy and Novel Model

  2016cites this paper
• Homozygous PPT1 Splice Donor Mutation in a Cane Corso Dog With Neuronal Ceroid Lipofuscinosis

  2016cites this paper
• Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease.

  2016cites this paper
• Reversible Cysteine Acylation Regulates the Activity of Human Palmitoyl-Protein Thioesterase 1 (PPT1)

  2016cites this paper
• Combined Therapies for Lysosomal Storage Diseases.

  2015cites this paper
• Towards a new understanding of NCL pathogenesis.

  2015cites this paper
• Advances in the treatment of neuronal ceroid lipofuscinosis

  2013cites this paper
• Journal Pre-proof Targeting the Central Nervous System in Lysosomal Storage Diseases: Strategies to Deliver Therapeutics Across the Blood-Brain Barrier

  year unknowncites this paper